UPDATE 2-U.S. approves Roche's $4.3 billion purchase of Spark Therapeutics

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for Roche's push into treating rare diseases including hemophilia A.